This observation is in agreement with a recent report[6], which has documented much less β-catenin and lymphoid enhancer-binding factor 1 (LEF-1, a direct target of the pathway[47]) in the CLL cell lines JVM-1 and MEC-1 in comparison with the patient samples. The gene discussed is LEF1; the disease is B-cell chronic lymphocytic leukemia.